(firstQuint)A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty (CPP) Among Chinese Participants.

 The drug being evaluated in this study is called leuprorelin.

 Leuprorelin is used to treat children who have CPP.

 This study will look at long term safety and efficacy of leuprorelin in the treatment of Chinese participants with CPP.

 The study will enroll approximately 300 participants.

 All participants who have received leuprorelin 30 mcg/kg to <90 mcg/kg or 90 mcg/kg to 180 mcg/kg per body weight, injection, subcutaneously, every 4 weeks up to at least 9 continuous months during the index period from September 1st 1998 to September 30th 2018 will be observed.

 This multi-center trial will be conducted in China.

 Data will be collected over period of 20 months.

.

 A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty (CPP) Among Chinese Participants@highlight

The purpose of this study is to evaluate the long-term safety and efficacy of leuprorelin in the treatment of CPP (of at least 9 months of ENANTONE) in Chinese participants.

